88IV - PR Newswire Asia's news


Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist ... 2026-09-09T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer ... 2026-09-09T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit HCB101 represents the first known U.S. Expanded Access case for a SIRPα Fc fusion protein enabling continued therapy beyond the parent study. ... 2026-09-09T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
ZAGENO Earns Frost & Sullivan's 2026 North American Life Sciences E‑Commerce Company of the Year Recognition Honored for transforming life sciences procurement through digital innovation, automation, and a customer-first platform ... 2026-09-09T Biotechnology Computer Software Electronic Commerce
Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026 Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysis ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Metabolon Verus™ Metabolomics Profiling Kit Now Available to Order A successful multi-site ring trial and early access program demonstrate the reproducibility, scalability, and biological insight of the Metabolon Verus™ Metabolomics Profiling Kit across laboratories ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo NEW YORK and SUZHOU, China , Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy SHANGHAI , Sept. 8, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced ... 2026-09-08T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 ... 2026-09-08T Biotechnology Health Care/Hospital Medical Equipment Medical/Pharmaceuticals

PR Newswire Asia's news > Biotechnology